Single award · contract
COVID-19 Oral Antiviral MK-4482 (Molnupiravir)
Award ID: W911QY21C0031
FY2021 · complete year · data as of 2026-07-12
A single federal award, with both ends of the trail linked.
$2.2B
Total award value
Award W911QY21C0031 is a contract from the Department of Defense to Merck Sharp & Dohme LLC, $2.2B obligated, FY2021 to FY2023, for COVID-19 Oral Antiviral MK-4482 (Molnupiravir). The work is performed in New Jersey. It is classified as NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC 6505 (Drugs and Biologicals). Source
Agency ›
Department of Defense
Source
awarded→$2.2B
Recipient ›
Merck Sharp & Dohme LLC
Source
performed in→
Award details
Award typeContract
PIIDW911QY21C0031
Action date2021
Period25 mo
Awarding agencyDepartment of Defense →
RecipientMerck Sharp & Dohme LLC →
Place of performanceNew Jersey →
CategoryNAICS 325412PSC 6505
Competed?Not recordedSource
Total (exact)$2,205,000,834
More awards to Merck Sharp & Dohme LLC
awarded 2014$1.5B
awarded 2017$1.5B
awarded 2013$1.4B
awarded 2012$1.4B
awarded 2011$1.3B
More from Department of Defense
awarded 2016$51.3B
awarded 2017$35.7B
awarded 2017$35.1B
awarded 2001$34.2B
awarded 2011$32B
Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are Source; figures we calculate are Computed; links we infer (corporate parents, districts, similar contractors, connections between records) are Inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.